Please read these Terms of Use and Privacy Statement (collectively, the "Terms") carefully before using any of the box above indicates that you accept these Terms.
Following specialists treat CINCA. Help us improve our data based on your experience.
100%
100%
100%
100%
100%
0%20%40%60%80%
Specialty scores for CINCA
Trade Name: Canakinumab
Indication: Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older. Also approved for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.